U.S. Induced Pluripotent Stem Cell (iPSC) Market Size Worth USD 1,372.22 Million by 2032 | CAGR: 9.6%

The U.S. Induced Pluripotent Stem Cell (iPSC) market size is expected to reach USD 1,372.22 Million by 2032, according to a new study by Polaris Market Research. The report “U.S. iPSC Market Share, Size, Trends, Industry Analysis Report, By Derived Cell (Hepatocytes, Fibroblasts, Neural Cells, Amniotic Cells, Cardiomyocytes, Others); By Workflow; By Application; Segment Forecast, 2024 - 2032” gives a detailed insight into current market dynamics and provides analysis on future market growth.

The United States market for induced pluripotent stem cells (iPSC) has experienced significant growth in recent years, primarily due to advancements in research activities in drug discovery and toxicology testing, regenerative medicine, and stem cell research investments. iPSCs have enormous potential for disease modeling, drug development, and personalized medicine, which is driving their demand for various biomedical applications.

One of the key trends shaping the U.S. iPSC market is the increasing prevalence of chronic diseases, such as cancer, neurodegenerative disorders, and cardiovascular diseases. The use of iPSC technology is emerging as a promising tool for disease modeling, enabling researchers to delve into disease mechanisms, screen potential therapeutics, and develop personalized treatment approaches. The adoption of iPSC-based therapies, particularly in regenerative medicine, is on the rise, which reflects their potential to address unmet medical needs and drive market growth.

Do you have any questions? Would you like to request a sample or make an inquiry before purchasing this report? Simply click the link below:https://www.polarismarketresearch.com/industry-analysis/us-induced-pluripotent-stem-cell-ipsc-market/request-for-sample

The U.S. iPSC market is being propelled by advancements in stem cell research and the increasing demand for personalized medicine. iPSCs are highly versatile and can serve as an infinite source of specialized cells for transplantation or disease modeling, making them a major focus of extensive research and development. This has resulted in significant technological advancements and a growing number of clinical trials exploring the therapeutic potential of iPSCs. However, the U.S. iPSC market is hindered by the strict regulatory framework governing the use of iPSCs in research and clinical applications.

U.S. iPSC Market Report Highlights

• The cell culture segment holds a dominant revenue share within the workflow segment of the market due to its crucial role in the production and maintenance of induced pluripotent stem cells (iPSCs). Cell culture techniques are considered the foundation of iPSC research and development as they enable the expansion, maintenance, and differentiation of iPSCs into diverse cell types.
• In the U.S. iPSC market, the regenerative medicine segment is expected to experience significant growth in the coming years, primarily due to the remarkable therapeutic potential of induced pluripotent stem cells (iPSCs) in treating a diverse range of medical conditions.
• The U.S. key market players include Applied StemCell, Astellas Pharma Inc., Catalent, Inc, Evotec, Fate Therapeutics, FUJIFILM Holdings Corporation (Cellular Dynamics), REPROCELL Inc., Takara Bio Inc., Thermo Fisher Scientific Inc., ViaCyte, Inc, and among others.

Polaris Market Research has segmented the U.S. iPSC market report based on derived cell, workflow, and application:

U.S. iPSC, Derived Cell Outlook (Revenue - USD Million, 2019 - 2032)

• Hepatocytes
• Fibroblasts
• Neural Cells

• Excitatory Neurons
• Inhibitory Neurons

• Amniotic Cells
• Cardiomyocytes
• Others

U.S. iPSC, Workflow Outlook (Revenue - USD Million, 2019 - 2032)

• Reprogramming
• Cell Culture
• Cell Characterization / Analysis
• Engineering
• Others

U.S. iPSC, Application Outlook (Revenue - USD Million, 2019 - 2032)

• Manufacturing
• Academic Research
• Drug Development & Discovery
• Toxicity Screening
• Regenerative Medicine

U.S. Induced Pluripotent Stem Cell (iPSC) Market Report Scope